OMER STOCK ACTIVATOR
OMS906, its inhibitor of MASP-3, an activator of the alternative pathway of complement, is initiating a Phase I b clinical program in paroxysmal nocturnal hemoglobinuria (PNH). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome, and COVID-19.
OMER STOCK LICENSE
Its lead lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Least 15 minutes stock quote data powered by Ticker Technologies, and Mergent.Omeros Corporation is a biopharmaceutical company. Video widget and market videos powered by Market News Video.
OMER STOCK FULL
By visiting, using or viewing this site, youĪgree to the following Full Disclaimer & Terms of Use and Liable for any loss or damage caused by your reliance on information obtained. its subsidiaries, partners, officers, employees, affiliates, or agents be held All viewers agree that under noĬircumstances will BNK Invest, Inc.
Transaction, or investment strategy is suitable for any specific person. None of the information contained herein constitutes a recommendation that any particular security, portfolio,
or any of its affiliates, subsidiaries or partners.
Nothing in Shares Outstanding is intended to be investment advice, nor does it represent the opinion of, counselįrom, or recommendations by BNK Invest Inc. Start investing in Omeros Corporation stocks from India now with fractional. With this page we aim to empower investors researching OMER by allowing them to research OMER shares outstanding historyĪs well as any other stock in our coverage universe.Ĭopyright © 2017 - 2022, All Rights Reserved Buy Omeros Corporation Shares from India at 3.31 (0 Commission) today. We hire smart, creative and hard-working people who want to play a meaningful part in building a preeminent biopharmaceutical company. P/E Ratio, 1.9203, Dividend Yield, 0.0, EPS, -1.03. The Omeros team is exceptionally talented, passionate, collaborative and diverse. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.įurthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. Market Cap, 359.443 Million, Shares Outstanding, 62.73 Million, Avg 30-day Volume, 778.047 Thousand. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading atĪ price of $20 per share and think the latter company is worth twice as much. Understanding the changing numbers of OMER shares outstanding - andĬomprehending the concept of differing number of shares outstanding in general comparing companies like OMER versus peers.
We show 52 historical shares outstanding datapoints in our coverage of OMER's shares outstanding history. has various late-stage clinical development programs in its pipeline, which are focused on: complement-mediated disorders, including immunoglobulin A nephropathy, atypical hemolytic uremic syndrome and COVID-19. Stock quote and company snapshot for OMEROS CORP (OMER), including profile, stock chart, recent news and events, analyst opinions, and research reports. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Co.'s drug candidate narsoplimab is the subject of a biologics license application pending before the U.S. is focused on discovering, developing and commercializing small-molecule and protein therapeutics for larger-market as well as orphan indications targeting immunologic diseases. Omeros is a commercial-stage biopharmaceutical company. Below is a table of the OMER shares outstanding history going back to :
0 kommentar(er)
